Angiotensin II

Generic Name: Angiotensin II

Brand Names: Giapreza

Drug Type: Biotech

CAS Number: 4474-91-3

Unique Ingredient Identifier: M089EFU921

Background: Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.

As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.

Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do not adequately respond to currently available therapies.

Indication: Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock .

Associated Conditions: Hypotension

Clinical Trials

Dysfunctional Renin-Angiotensin System in Septic Shock

Phase 4

Not yet recruiting

Conditions: Septic Shock

Interventions: Drug: Angiotensin II
Drug: Norepinephrine

First Posted Date: 2024-12-24

Last Posted Date: 2025-03-25

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 78

Registration Number: NCT06746753

Locations: 🇺🇸
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States

Early Angiotensin II in the Emergency Department

Phase 4

Recruiting

Conditions: Septic Shock

Interventions: Drug: Angiotensin II Infusion

First Posted Date: 2024-11-18

Last Posted Date: 2025-04-02

Lead Sponsor: Brett A Faine

Target Recruit Count: 20

Registration Number: NCT06693726

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Phase 3

Not yet recruiting

Conditions: Cardiac Surgery
Vasoplegia

Interventions: Drug: Angiotensin II
Drug: Noradrenalin

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Universität Münster

Target Recruit Count: 1022

Registration Number: NCT06615102

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Phase 4

Not yet recruiting

Conditions: Hypotension After Cardiac Surgery

Interventions: Drug: Angiotensin II

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: University of Maryland St. Joseph Medical Center

Target Recruit Count: 100

Registration Number: NCT06487585

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Phase 3

Recruiting

Conditions: Vasodilatory Shock

Interventions: Drug: Angiotensin II Injection
Drug: 0.9% sodium chloride injection

First Posted Date: 2024-04-08

Last Posted Date: 2025-01-23

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 214

Registration Number: NCT06351150

Locations: 🇨🇳
Liuzhou General Hospital, Liuzhou, Guangxi, China
🇨🇳
The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳
The Frist Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

and more 39 locations